The most common KMT2A fusion partners in AML patients include AF9 (MLLT3), AF10 (MLLT10), KMT2A-PTDs, ELL, AF6 (AFDN), ENL (MLLT1), and MLLT11 (Table 1) [12]. Here, MLLT1 is linked to acute myeloid leukemia.